Related Experiment Videos
Noscapine does not show aneugenic activity in mouse oocytes
C Tiveron1, B Hartley-Asp, C J Johansson
1Division of Toxicology, ENEA CRE Casaccia, Roma, Italy.
Mutagenesis
|July 1, 1993
Summary
Noscapine did not induce polyploidy or chromosome errors in mouse oocytes, even at high doses. This suggests noscapine is unlikely to pose a genetic risk to humans at therapeutic levels.
Area of Science:
- Toxicology
- Genetics
- Pharmacology
Background:
- Noscapine is an alkaloid used for its antitussive properties.
- Potential genotoxicity of pharmaceutical compounds requires thorough investigation.
- Understanding noscapine's effects on germ cell chromosomes is crucial for safety assessment.
Purpose of the Study:
- To investigate the potential of noscapine to induce polyploidy in rodent germ cells in vivo.
- To establish the relationship between noscapine plasma concentrations, area under the curve (AUC), and meiotic progression.
- To assess the genetic risk of noscapine at therapeutic dosages.
Main Methods:
- Cytogenetic study of mouse metaphase II oocytes after oral noscapine administration (20, 120, 400 mg/kg).
- Measurement of noscapine plasma concentrations using reversed-phase liquid chromatography and UV detection.
- Evaluation of meiotic progression, chromosome malsegregation, and oocyte ploidy.
Main Results:
- No significant increase in polyploid or hyperploid oocytes was observed across tested doses.
- No delay in meiotic progression or induction of chromosome malsegregation was detected.
- A significant decrease in oocyte yield occurred only at the highest dose, affecting superovulation.
Conclusions:
- Noscapine does not appear to induce polyploidy or chromosome malsegregation in mouse oocytes in vivo.
- Pharmacokinetic data suggest a low likelihood of genetic risk in humans at therapeutic noscapine doses.
- Further research may explore other potential toxicological endpoints at higher concentrations.